CD274 and neoplasm: In this multivariate analysis, PD-L1 expression in tumors (1–50% and 50–100%) was significantly associated with a lower risk of tumor progression over 12 months; this was not observed for patients with tumors that scored in the range of 0–1% (Figure 5A).